secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001564590-21-055942
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q3 net loss $19.1M; initiates SUMMIT Phase 2, cash $202.9M
-----------------------------------------------------------------------------

- Net loss of $19.1M in Q3 2021 vs $50.0M in Q3 2020 (prior included $46.9M asset acquisition charge).
- Cash and equivalents $202.9M; expected to fund operations into 2024.
- Initiated SUMMIT Phase 2 trial for bezuclastinib in nonadvanced systemic mastocytosis.
- APEX Phase 2 trial for AdvSM on track for preliminary data readout H1 2022.
- Appointed Dana Martin as Chief Patient Officer and Courtney Watson as VP Clinical Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000156459021055942/0001564590-21-055942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000156459021055942/cogt-8k_20211110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer